{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:58:49Z","timestamp":1718222329184},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00508-016-0984-y","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T18:05:21Z","timestamp":1458324321000},"page":"435-441","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Crizotinib-induced toxicity in an experimental rat model"],"prefix":"10.1007","volume":"128","author":[{"given":"Ozge","family":"Gumusay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guldal","family":"Esendagli-Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aytug","family":"Uner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Buyukberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Benekli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa N.","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Gulbahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Ozet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"issue":"2","key":"984_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"984_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"984_CR3","first-page":"56","volume":"75","author":"LG Collins","year":"2007","unstructured":"Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56\u201363.","journal-title":"Am Fam Physician"},{"issue":"3","key":"984_CR4","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.07-1860","volume":"132","author":"WM Alberts","year":"2007","unstructured":"Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007;132(3 Suppl):1S\u201319S.","journal-title":"Chest"},{"issue":"21","key":"984_CR5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339.","journal-title":"N Engl J Med"},{"issue":"5676","key":"984_CR6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","journal-title":"Science"},{"issue":"18","key":"984_CR7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693\u2013703.","journal-title":"N Engl J Med"},{"issue":"7153","key":"984_CR8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature"},{"issue":"5","key":"984_CR9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","volume":"6","author":"SH Ou","year":"2011","unstructured":"Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942\u20136.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"984_CR10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011\u20139.","journal-title":"Lancet Oncol"},{"issue":"25","key":"984_CR11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"7","key":"984_CR12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ejca.2012.02.001","volume":"48","author":"RA Stahel","year":"2012","unstructured":"Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48(7):961\u201373.","journal-title":"Eur J Cancer"},{"key":"984_CR13","doi-asserted-by":"crossref","unstructured":"Crin\u00f2 L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29 (suppl; abstr 7514).","DOI":"10.1200\/jco.2011.29.15_suppl.7514"},{"key":"984_CR14","unstructured":"Smith EB, Goulet L, Walker GS, et al. Metabolism and excretion of Crizotinib in rats and dogs. 17th North American Regional International society for the study of xenobiotics Meeting. (P82)."},{"issue":"8","key":"984_CR15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863\u201370.","journal-title":"J Clin Oncol"},{"key":"984_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/1471-2407-14-683","volume":"14","author":"H Qian","year":"2014","unstructured":"Qian H, Gao F, Wang H, et al. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14:683.","journal-title":"BMC Cancer"},{"issue":"5","key":"984_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","volume":"5","author":"Y Loriot","year":"2008","unstructured":"Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268\u201378.","journal-title":"Nat Clin Pract Oncol"},{"issue":"2","key":"984_CR18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejca.2011.10.011","volume":"48","author":"U Demirci","year":"2012","unstructured":"Demirci U, Buyukberber S, Y\u0131lmaz G, et al. Hepatotoxicity associated with lapatinib in an experimental rat model. Eur J Cancer. 2012;48(2):279\u201385.","journal-title":"Eur J Cancer"},{"issue":"1","key":"984_CR19","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clinre.2012.10.003","volume":"37","author":"MP Ripault","year":"2013","unstructured":"Ripault MP, Pinzani V, Fayolle V, et al. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol. 2013;37(1):e21\u20133.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"984_CR20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jjco\/hyu086","volume":"44","author":"Y Sato","year":"2014","unstructured":"Sato Y, Fujimoto D, Shibata Y, et al. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J Clin Oncol. 2014;44(9):872\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"984_CR21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.meg.0000216941.42306.0e","volume":"18","author":"A Pariente","year":"2006","unstructured":"Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006;18(7):785\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"984_CR22","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"HM Shulman","year":"2002","unstructured":"Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310\u20134.","journal-title":"Blood"},{"issue":"26","key":"984_CR23","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1200\/JCO.2012.47.1110","volume":"31","author":"A Ono","year":"2013","unstructured":"Ono A, Takahashi T, Oishi T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol. 2013;31(26):e417\u20139.","journal-title":"J Clin Oncol"},{"key":"984_CR24","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","volume":"91","author":"NL Muller","year":"2004","unstructured":"Muller NL, White DA, Jiang H, et al. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91:S24\u2013S30.","journal-title":"Br J Cancer"},{"key":"984_CR25","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"984_CR26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.bjc.6602065","volume":"91","author":"T Higenbottam","year":"2004","unstructured":"Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S31\u20137.","journal-title":"Br J Cancer"},{"issue":"9352","key":"984_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361(9352):137\u20139.","journal-title":"Lancet"},{"issue":"2","key":"984_CR28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","volume":"120","author":"S Sleijfer","year":"2001","unstructured":"Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617\u201324.","journal-title":"Chest"},{"issue":"5","key":"984_CR29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pan.2013.08.001","volume":"13","author":"SH Tirumani","year":"2013","unstructured":"Tirumani SH, Jagannathan JP, Shinagare AB, et al. Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology. 2013;13(5):461\u20137.","journal-title":"Pancreatology"},{"issue":"1","key":"984_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3747\/co.21.1740","volume":"21","author":"JM Rothenstein","year":"2014","unstructured":"Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol. 2014;21(1):19\u201326.","journal-title":"Curr Oncol"},{"issue":"3","key":"984_CR31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2014.03.001","volume":"84","author":"P Mart\u00edn Martorell","year":"2014","unstructured":"Mart\u00edn Martorell P, Huerta Alvaro M, Sol\u00eds Salguero MA, et al. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer. 2014;84(3):310\u20133.","journal-title":"Lung Cancer"},{"issue":"5","key":"984_CR32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","volume":"120","author":"EM Brosnan","year":"2014","unstructured":"Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120(5):664\u201374.","journal-title":"Cancer"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-0984-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-016-0984-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-0984-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T14:39:11Z","timestamp":1567694351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-016-0984-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":32,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s00508-016-0984-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]}}}